Dualistic Classification of Epithelial Ovarian Cancer: Surgical and Survival Outcomes in a Large Retrospective Series
详细信息 查看全文
- 作者：Pierluigi Benedetti Panici MD (1)
Claudia Marchetti MD (1)
Laura Salerno MD (1)
Angela Musella MD (1)
Laura Vertechy MD (1)
Innocenza Palaia MD (1)
Giorgia Perniola MD (1)
Ilary Ruscito MD (1)
Terenzio Boni MD (1)
Roberto Angioli MD (2)
Ludovico Muzii MD (1) - 刊名：Annals of Surgical Oncology
- 出版年：2014
- 出版时间：September 2014
- 年：2014
- 卷：21
- 期：9
- 页码：3036-3041
- 全文大小：240 KB
- 参考文献：1. Seidman JD, Yemelyanova A, Cosin JA, Smith A, Kurman RJ. Survival rates for International Federation of Gynecology and Obstetrics stage III ovarian carcinoma by cell type: a study of 262 unselected patients with uniform pathologic review. / Int J Gynecol / Cancer. 2012;22:36-1. CrossRef
2. Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. / Am J Pathol. 2004;164:1511-. CrossRef
3. Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—shifting the paradigm. / Hum Pathol. 2011;42:918-1. CrossRef
4. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. / Am J Surg Pathol. 2010;34:433-3. CrossRef
5. McAlpine JN, Porter H, Kobel M, et al. BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. / Mod Pathol. 2012;25:740-0. CrossRef
6. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary FIGO 26th annual report on the results of treatment in gynecological cancer. / Int J Gynaecol Obstet. 2006; Suppl 1:S161–S192. CrossRef
7. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. / Int J Gynecol Pathol. 2000;19:7-5. CrossRef
8. BenedettiPanici P, DeVivo A, Bellati F, et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. / Ann Surg Oncol. 2007;14:1136-2. CrossRef
9. Braicu EI, Sehouli J, Richter R, Pietzner K, Denkert C, Fotopoulou C. Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers. / Br J Cancer. 2011;105:1818-4. CrossRef
10. Bamias A, Sotiropoulou M, Zagouri F, et al. Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor. / Eur J Cancer. 2012;48:1476-3. CrossRef
11. Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. / Adv Anat Pathol. 2009;16:267-2. CrossRef
12. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol. 2005;18(Suppl 2):19-2. CrossRef
13. Chen X, Zhang J, Cheng W, et al. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer. / Int J Gynecol Cancer. 2013;23:815-2. CrossRef
14. Kajiyama H, Shibata K, Mizuno M, et al. Postrecurrent oncologic outcome of patients with ovarian clear cell carcinoma. / Int J Gynecol Cancer. 2012;22:801-. CrossRef
15. Kajiyama H, Shibata K, Mizuno M, et al. Long-term clinical outcome of patients with recurrent epithelial ovarian carcinoma: is it the same for each histological type? / Int J Gynecol Cancer. 2012;22:394-. CrossRef
16. Kajiyama H, Mizuno M, Shibata K, Kawai M, Nagasaka T, Kikkawa F. Extremely poor postrecurrence oncological outcome for patients with recurrent mucinous ovarian cancer. / Int J Clin Oncol. 2014; 19(1):121-26 CrossRef
17. Gershenson DM, Sun CC, Bodurka D, et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. / Gynecol Oncol. 2009;114:48-2. CrossRef
18. Pignata S, Ferrandina G, Scarfone G, et al. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6?months: results from the SOCRATES retrospective study. / BMC Cancer. 2008;1;8:252. CrossRef
19. Vergote I, Tropé CG, Amant F, et al European Organization for Research and Treatment of Cancer–Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. / N Engl J Med. 2010;363:943-3. CrossRef
20. Chang SJ, Bristow RE. Evolution of surgical treatment paradigmsfor advanced-stage ovarian cancer: redefining “optimal-residual disease. / Gynecol Oncol. 2012;125:483-2. CrossRef - 作者单位：Pierluigi Benedetti Panici MD (1)
Claudia Marchetti MD (1)
Laura Salerno MD (1)
Angela Musella MD (1)
Laura Vertechy MD (1)
Innocenza Palaia MD (1)
Giorgia Perniola MD (1)
Ilary Ruscito MD (1)
Terenzio Boni MD (1)
Roberto Angioli MD (2)
Ludovico Muzii MD (1)
1. Department of Gynecological and Obstetrical Sciences and Urological Sciences, Sapienza University of Rome, Rome, Italy
2. Department of Gynecology, Campus Bio-Medico University of Rome, Rome, Italy - ISSN：1534-4681
文摘
Background Ovarian cancers have been recently categorized into types I and II according to a dualistic model of tumorigenesis. Data on the correlation between this classification and clinical outcome are still scarce and controversial. Methods A retrospective analysis of patients with ovarian cancer treated from 1998 to 2013 and operated by the same surgeon was conducted. Patients were classified into two groups: type I (125 patients), including low-grade serous, mucinous, endometrioid, and clear cell tumors; and type II (286 patients), including high-grade serous tumors, unspecified adenocarcinomas, and undifferentiated carcinomas. Results Type II patients had a significantly higher incidence of advanced disease than type I (88.4 vs. 65.6?%, P?=?0.0001) and required more aggressive surgical procedures. Rates of optimal tumor debulking were almost similar between groups (92.6 vs. 91.7?%, type I vs. II, P?=?NS). After a median follow-up of 41?months, 207 patients (50.4?%) were alive and 204 (49.6?%) were dead; 79 type I patients (63.8?%) and 237 type II patients (82.7?%) experienced relapse (P?=?0.02). Progression-free survival was significantly different between groups: 25?months for type I vs. 17?months for type II (P?=?0.023). Overall survival was not significantly different between groups, with a median overall survival of 75?months for type I vs. 62?months for type II (P?=?0.116). Conclusions The dualistic histotype-based classification into types I and II of ovarian cancer does not seem to correlate with prognosis. Different molecular characteristics of type I and II tumors may have therapeutic implications and should be deeply investigated.